Combined effects of Er: YAG laser irradiation and GLUMA in the treatment of occlusal dentine hypersensitivity induced by tooth wear: a randomized controlled trial
摘要
To evaluate the therapeutic effect of Er:YAG laser irradiation combined with GLUMA on dentine hypersensitivity (DH) induced by tooth wear and to provide clinical evidence for the treatment of DH.
MethodsA total of 224 DH-affected teeth from 77 patients with tooth wear were included and randomly divided into 3 groups according to the application of different desensitization methods. Specifically, 75 teeth were desensitized with GLUMA in Group A; 76 teeth were desensitized with a 2940-nm Er:YAG laser in Group B; and 73 teeth were desensitized with an Er:YAG laser combined with GLUMA in Group C. A visual analog scale (VAS) was used to evaluate the sensitivity of teeth to air-blast stimulus, cold stimulus, and tactile stimulus before treatment, immediately after treatment, and 1 week, 1 month, 3 months, 6 months, and 9 months after treatment.
ResultsAll treatments relieved DH symptoms instantly. The VAS scores for the air-blast stimulus, cold stimulus, and tactile stimulus immediately after treatment and at all the measured time points during the follow-up period were significantly lower in Groups B and C than in Group A (P < 0.05). No significant differences were found between Groups B and C immediately, 1 week, or 1 month after treatment (P > 0.05), although the values in Group C were lower than those in Group B. At the third month of follow-up and beyond, the scores in Group C were significantly lower than those in Group B (P < 0.05). In addition, the VAS scores for all stimuli increased gradually during the follow-up period. At the end of follow-up, the scores in Groups B and C were still lower than those before treatment (P < 0.05), but similar results were not confirmed for Group A (P > 0.05).
ConclusionEr:YAG laser irradiation combined with GLUMA is more effective than GLUMA or laser irradiation alone in the treatment of DH induced by tooth wear, and the efficacy can be maintained for at least 9 months.
Trial registration: The trial was registered with ClinicalTrials.gov (ID: ChiCTR2500097345; 2025–02-18; Retrospectively registered).